Tessa Therapeutics Receives PRIME Designation from European Medicines Agency for CD30 CAR-T Therapy January 18, 2021 Tessa Therapeutics Appoints David McIntyre as Chief Financial Officer December 17, 2020 Tessa Therapeutics Announces Results from Two Independent Phase 1/2 Trials of Autologous CD30 CAR-T Cell Therapy in Patients with Relapsed or Refractory Hodgkin... August 6, 2020 Tessa Therapeutics Announces New Executive Leadership May 4, 2020 Tessa Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to its CD30 CAR-T Cell Therapy for the Treatment of Rela... February 27, 2020 Tessa Therapeutics to Open 90,000 Square Foot Commercial-Scale Cell Therapy Manufacturing Facility in Singapore in 2020 December 19, 2019 Tessa Therapeutics Establishes New Scientific Advisory Board May 22, 2019 Tessa Therapeutics, in Collaboration with Baylor College of Medicine, Presents Preclinical Results Showing Enhanced T Cell Responses Against HER2-Positive Solid... April 30, 2019 Biopharma veteran, Jeffrey H. Buchalter is our newest independent board director February 28, 2019 Distinguished breast cancer expert, Dr. George W. Sledge, Jr., M.D., joins our Board December 21, 2018